Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 1-10 of 21

Page
per page
  1. TAE684 (NVP-TAE684)
    A8251 TAE684 (NVP-TAE684)
    Summary: ALK inhibitor,potent and selective
      ≥61.4 mg/mL
  2. SB525334
    A5602 SB525334
    Summary: (TGF-beta1) receptor inhibitor
      ≥34.3 mg/mL
  3. ALK-IN-1
    A1367 ALK-IN-1
    Summary: Anaplastic lymphoma kinase (ALK) inhibitor
      ≥26.45 mg/mL
  4. LDN-193189
    A8324 LDN-193189
    Target: BMP and Other Activin Receptors
    Summary: ALK inhibitor,potent and selective
      insoluble in DMSO; insoluble in EtOH; insoluble in H2O
  5. LDK378
    A8328 LDK378
    Target: ALK
    Summary: Potent ALK inhibitor
      insoluble in H2O; ≥13.95 mg/mL
  6. GSK1838705A
    A8440 GSK1838705A
    Target: Insulin and Insulin-like Receptors|ALK
    Summary: IGF-IR/IR/ALK inhibitor, ATP-competitive
      ≥26.65 mg/mL
  7. CH5424802
    A8393 CH5424802
    Target: ALK
    Summary: ALK inhibitor,potent and ATP-competitive
  8. AZD-3463
    A8620 AZD-3463
     3 Citation
    Target: ALK|Insulin-like growth factors (IGFs)
    Summary: ALK/IGF1R inhibitor
      insoluble in H2O; insoluble in EtOH; ≥11.22 mg/mL
  9. LDK378 dihydrochloride
    A3544 LDK378 dihydrochloride
    Summary: ALK inhibitor
  10. LDN193189 Hydrochloride
    A3545 LDN193189 Hydrochloride
     1 Citation
    Summary: ALK inhibitor,potent and selective
      ≥27.6 mg/mL

Items 1-10 of 21

Page
per page